Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    Sareum Holdings

    MCap

    GBP26m

    Last close

    GBP0.29

    ▲ 3.50 (13.73%)

    IRLAB Therapeutics

    MCap

    SEK596m

    Last close

    SEK13.05

    ▲ 1.55 (13.48%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

IRLAB Therapeutics (OMX: IRLAB-A)

Last close As at 13/05/2024

SEK13.05

▲ 1.55 (13.48%)

Market capitalisation

SEK596m

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

Latest Insights

View More

Healthcare | Update

IRLAB Therapeutics — External validation boosts quarterly recap

Healthcare | Flash note

IRLAB Therapeutics — MSRD agreement early validation for IRL757

Healthcare | Update

IRLAB Therapeutics — Beyond PD-LID, a closer look at PD-psychosis

Healthcare | Flash note

IRLAB Therapeutics — FDA thumbs up to mesdopetam’s Phase III plan
IRLAB Therapeutics_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Viktor Siewertz

    CFO

Balance Sheet

Forecast net cash (SEKm)

74.2

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (15.1) (10.9) 23.1
Relative (16.2) (18.4) 6.5
52 week high/low SEK19.6/SEK5.9

Financials

In its Q124 report, IRLAB recapped its efforts in targeting major aspects of Parkinson’s disease (PD). The update was enhanced by the recently announced R&D collaboration for IRL757, which is anticipated to fully fund all development activities through clinical proof-of-concept and support the advancement of the development programme through efficacy signal readouts in both PD and Alzheimer’s patient populations. IRLAB will take the compound into a Phase I study, funded by the MJFF, later this month. Both of IRLAB’s most advanced assets continue to progress through the clinic, with management gearing up for Phase III for mesdopetam and ongoing patient enrolment for pirepemat (Phase IIb). Gross cash at end Q124 of SEK73.1m, with receipt of the US$3.0m upfront payment from the McQuade Center for Strategic Research and Development (MSRD) and drawdown of the remaining SEK25m (SEK55m facility), should see operations into Q125, past key events. Our valuation increases to SEK4.25bn or SEK81.9/share from SEK4.04bn or SEK77.9/share.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 61.3 (108.3) (113.1) (218.0) N/A N/A
2023A 5.7 (176.5) (177.8) (343.0) N/A N/A
2024E 0.0 (185.5) (191.3) (369.0) N/A N/A
2025E 0.0 (173.6) (189.7) (366.0) N/A N/A

Research

Flash note

Healthcare

IRLAB Therapeutics — MSRD agreement early validation for IRL757

Update

Healthcare

IRLAB Therapeutics — Beyond PD-LID, a closer look at PD-psychosis
DSF9408

Healthcare

Update

IRLAB Therapeutics — External validation boosts quarterly recap

DSF9408
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free